AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02780739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness
Description: Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills \& Skills; and Cool-down/stretch.
Study NCT02780739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
Study NCT02780739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
Study NCT02780739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
Study NCT02780739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training - 20 sessions
Description: Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
Study NCT03101852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Nut
Study NCT03101852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Sup
Study NCT00671827 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires each taking less than 10 minutes to complete.
Study NCT01404208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: 25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
Study NCT01404208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT00739505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa
Description: The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC.
Study NCT00739505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa
Description: Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
Study NCT03589118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong sessions
Description: 13 sessions of Qi Gong in a 9 weeks period
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Bolus 400mg/m2, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 165mg/m2 1-hour iv infusion, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv day 1 every 2 weeks
Study NCT00778102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv day 1 every 2 weeks
Study NCT01758198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Study NCT01758198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with Abatacept
Study NCT01758198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT01758198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study NCT00800605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived, trivalent, seasonal influenza vaccine
Description: Single intramuscular injection
Study NCT00800605 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Phosphate-buffered saline
Description: Single intramuscular injection
Study NCT03284372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Only
Description: The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
Study NCT03284372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message + Incentive 1
Description: Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
Study NCT00703287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Specialized physiotherapy programme developed by Jean-Pierre Bleton
Study NCT00703287 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy
Description: Generic physiotherapy
Study NCT01451632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: escalating doses MM-121 IV QW
Study NCT01451632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV Q2W
Study NCT01451632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: escalating doses cetuximab IV QW
Study NCT04240457 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.
Description: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
Study NCT04240457 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.
Description: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: Mean blood glucose
Description: Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: Blood glucose CV
Description: Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: % time 70-180 mg/dL
Description: Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: % time below 54 mg/dL
Description: Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: % time above 180 mg/dL
Description: Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: % time above 250 mg/dL
Description: Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: MAGE (Mean amplitude of glucose excursions)
Description: Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: LBGI (Low Blood Glucose Index)
Description: Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: OTHER
Intervention: HBGI (High Blood Glucose Index)
Description: High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
Study NCT03334318 — intervention group
Intervention type: DRUG
Intervention: Allopurinol
Description: Oral allopurinol tablets administered in the PERL Clinical Trial
Study NCT03334318 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Oral placebo tablets administered in the PERL Clinical Trial
Study NCT02672007 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SensiumVitals
Description: The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
Study NCT02035774 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LSIB + SSNB
Description: Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
Study NCT02035774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSIB + SSNB
Description: Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
Study NCT01549262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)
Description: Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
Study NCT01549262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Observe embryo development
Description: Observe embryo development in the traditional manner
Study NCT01455181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: 50, 75, 100 μg
Study NCT04747444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Gravity Treadmill
Description: Treadmill in which the body weight percent placed on the lower extremities can be controlled
Study NCT01378975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
Study NCT04472026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling using the electronic conversation aid
Description: This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
Study NCT03416634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App
Description: The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
Study NCT03416634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
Study NCT03416634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wearable Device
Description: A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
Study NCT03416634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable Device
Description: A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
Study NCT03416634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Motivational Message
Description: An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
Study NCT03416634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Motivational Message
Description: A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
Study NCT01465633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Study NCT01465633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Study NCT01420679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met.
Study NCT03077659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac®
Description: Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
Study NCT00787917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab subcutaneous injections of 600 mg daily.
Study NCT00787917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
Study NCT00787917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole twice daily with a maximum daily dose of 400 mg.
Study NCT00787917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Itraconazole twice daily with a maximum daily dose of 400 mg.
Study NCT06500923 — intervention group
Intervention type: OTHER
Intervention: Oral rehabilitation by means of implant-supported single unit crowns
Description: Surgery: Implant placement; Prothetic rehabilitation: single unit crown
Study NCT04907227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04907227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion
Study NCT04907227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study NCT04907227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral tablets
Study NCT04907227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral tablets
Study NCT04907227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT04907227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets
Study NCT04907227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets
Study NCT01616849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and 5-Fu combined with nimotuzumab
Description: DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week
Study NCT03462459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin capsule, 125 mg
Study NCT03462459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
Study NCT00634595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10A
Description: E10A 1\*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
Study NCT00634595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
Study NCT00634595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
Study NCT00634595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
Study NCT00634595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
Study NCT01681316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong injection
Description: A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower